What is the main announcement in this release?

Illumina's CGP test, 'TruSight Oncology Comprehensive', received insurance coverage in Japan starting June 1, 2026, and contract analysis has begun in partnership with Sysmex.

What are the features of TruSight Oncology Comprehensive?

It comprehensively analyzes 517 cancer-related genes in a single test, analyzing DNA and RNA mutations to identify biomarkers for treatment selection.

How many CGP panel tests are performed annually in Japan?

Approximately 20,000 CGP panel tests are performed annually in Japan.

When did this test receive approval from the Ministry of Health, Labour and Welfare?

It was approved as a highly controlled medical device (Class III) in May 2025.

Which company will perform the contract analysis?

The analysis will be performed by Riken Genesis Co., Ltd., a group company of Sysmex Corporation.

AI News NQ Analysis

Illumina Obtains Insurance Coverage for 'TruSight Oncology Comprehensive' Panel System

NQ Score 85/100

N1 Content Completeness 90

AI Summary (NQ-processed)

Illumina announced the start of contract analysis for the 'TruSight Oncology Comprehensive' CGP test at RIKEN GENESIS through a partnership with Sysmex, having obtained insurance coverage in Japan on June 1, 2026.

AI Analysis

Frequently Asked Questions

Q: What is the main announcement in this release?: A: Illumina's CGP test, 'TruSight Oncology Comprehensive', received insurance coverage in Japan starting June 1, 2026, and contract analysis has begun in partnership with Sysmex.
Q: What are the features of TruSight Oncology Comprehensive?: A: It comprehensively analyzes 517 cancer-related genes in a single test, analyzing DNA and RNA mutations to identify biomarkers for treatment selection.
Q: How many CGP panel tests are performed annually in Japan?: A: Approximately 20,000 CGP panel tests are performed annually in Japan.
Q: When did this test receive approval from the Ministry of Health, Labour and Welfare?: A: It was approved as a highly controlled medical device (Class III) in May 2025.
Q: Which company will perform the contract analysis?: A: The analysis will be performed by Riken Genesis Co., Ltd., a group company of Sysmex Corporation.